Eleven Biotherapeutics Inc  

(Public, NASDAQ:EBIO)   Watch this stock  
Find more results for EBIO
+0.009 (1.06%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.80 - 0.84
52 week 0.62 - 2.54
Open 0.81
Vol / Avg. 299,576.00/1.73M
Mkt cap 26.43M
P/E     -
Div/yield     -
EPS -1.06
Shares 31.83M
Beta 3.04
Inst. own 30%
Jan 9, 2018
Eleven Biotherapeutics Inc at EBD Group Biotech Showcase
Nov 15, 2017
Eleven Biotherapeutics Inc at Stifel Healthcare Conference
Nov 14, 2017
Q3 2017 Eleven Biotherapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - 6.31%
Operating margin - 9.56%
EBITD margin - 10.15%
Return on average assets -43.65% 2.68%
Return on average equity -169.96% 6.56%
Employees 34 -
CDP Score - -


245 1st St Ste 1800
CAMBRIDGE, MA 02142-1292
United States - Map
+1-617-4448550 (Phone)
+1-617-8580911 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company's therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

Officers and directors

Daniel S. Lynch Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Stephen A. Hurly President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Richard F. Fitzgerald CPA Interim Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Glen C. MacDonald Ph.D. Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
Gregory P. Adams Ph.D. Chief Development Officer
Age: 56
Bio & Compensation  - Reuters
Abbie C. Celniker Ph.D. Director
Age: 57
Bio & Compensation  - Reuters
Paul G. Chaney Director
Age: 59
Bio & Compensation  - Reuters
Wendy L. Dixon Ph.D. Director
Age: 61
Bio & Compensation  - Reuters
Jay S. Duker MD. Director
Age: 56
Bio & Compensation  - Reuters
Barry J. Gertz M.D. Ph.D. Director
Age: 65
Bio & Compensation  - Reuters